annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 37G Immunohistochemistry (IHC) with EGFR mutation-specific monoclonal
antibodies (mAbs) for screening EGFR mutations in non-small cell lung
cancer (NSCLC) patients (p). (Abstract #7570)
S. Simonetti, M. A. Molina, C. Mayo, J. Bertran-Alamillo, T. Moran, S. Benlloch,
S. Ramon y Cajal, I. I. Wistuba, M. Taron, R. Rosell
Brd. 37H The efficacy of low-dose gefitinib for advanced non-small cell lung cancer
(NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations:
A post-hoc analysis from NEJ002. (Abstract #7571)
A. Inoue, M. Maemondo, K. Kobayashi, S. Oizumi, H. Isobe, A. Gemma, Y. Saijo,
K. Hagiwara, S. Morita, T. Nukiwa
Brd. 38A Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR
mutations. (Abstract #7572)
W. Yeo, G. J. Riely, B. Yeap, M. W. Lau, J. Warner, K. A. Bodio, M. G. Kris,
W. Pao, S. Kobayashi, D. B. Costa
Brd. 38B Phase II study of erlotinib for acquired resistance to gefitinib in patients with
advanced non-small cell lung cancer. (Abstract #7573)
A. Horiike, N. Yamamoto, H. Tanaka, N. Yanagitani, K. Kudo, F. Ohyanagi,
T. Naito, H. Murakami, T. Horai, M. Nishio
Brd. 38C A phase I/IIa study of icotinib hydrochloride, a novel oral EGFR-TKI, to
evaluate its safety, tolerance, and preliminary efficacy in advanced NSCLC
patients in China. (Abstract #7574)
Q. Zhao, J. Zhou, J. Shentu, N. Xu, F. Tan
Brd. 38D Preliminary results of randomized phase III study comparing efficacy and
safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine
(GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients
(pts) with EGFR-activating mutations (OPTIMAL). (Abstract #7575)
C. Zhou, Y. Wu, G. Chen, J. Feng, X. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou,
S. Ren
Brd. 38E Preliminary results of a randomized phase II trial of first-line treatment of
gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in
patients 70 years or older with advanced non-small cell lung cancer (NSCLC).
(Abstract #7576)
T. Stinchcombe, D. S. Bradford, C. B. Lee, D. T. Moore, K. M. Bakri, M. A. Taylor,
J. M. Crane, G. Schwartz, T. A. Hensing, M. A. Socinski
Brd. 38F First- or second-line gefitinib therapy in unknown epidermal growth factor
receptor mutants of non-small cell lung cancer patients. (Abstract #7577)
C. Lie, M. Lin, T. Chao, J. Wang, H. Chang
Brd. 38G Efficacy and safety of bevacizumab in the treatment of advanced, nonsquamous
non-small cell lung cancer (NSCLC). (Abstract #7578)
D. Tassinari, F. Drudi, F. Carloni, S. Nicoletti, C. Possenti, C. Santelmo, L. Lazzari
Brd. 38H Comparison of response rate of advanced non-small lung cancer patients to
liposomal cisplatin versus cisplatin both combined with paclitaxel: A phase
III trial. (Abstract #7579)
G. Stathopoulos, D. Antoniou, J. Dimitroulis, J. Stathopoulos, K. Marosis,
P. Michalopoulou
Brd. 39A Open-label phase II study of S-1 as second-line therapy for patients with
advanced non-small cell lung cancer (NSCLC). (Abstract #7580)
R. Govindan, C. Zergebel, K. Saito, J. H. Schiller
Brd. 39B Phase II study of sunitinib in patients with non-small cell lung cancer
(NSCLC) and irradiated brain metastases: Final efficacy and safety results.
(Abstract #7581)
S. Novello, C. Camps, F. Grossi, J. Mazieres, L. E. Abrey, J. Vernejoux,
A. D. Thall, T. Usari, R. C. Chao, G. Scagliotti
Brd. 39F Systemic gene therapy with tumor suppressor FUS1-nanoparticles for
recurrent/metastatic lung cancer. (Abstract #7582)
C. Lu, D. J. Stewart, L. Ji, R. Ramesh, G. Jayachandran, J. J. Erasmus, J. Lee,
N. S. Templeton, J. D. McMannis, J. A. Roth
217
SUNDAY